Impact of ABO blood groups on tirofiban mediated inhibition of platelet function

References

• McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. Thromb Haemost 1983;50:757.
   PubMedGoogle Scholar
• Mohanty D, Ghosh K, Marwaha N, Kaur S, Chauhan AP, Das KC. Major blood group antigens–a determinant of factor VIII levels in blood? Thromb Haemost 1984;51:414.
   PubMedGoogle Scholar
• Souto JC, Almasy L, Muniz-Diaz E, Soria JM, Borrell M, Bayen L, Mateo J, Madoz P, Stone W, Blangero J, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000;20:2024–2028.
   PubMed Web of Science ®Google Scholar
• Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, Matsui T, Titani K, Katayama M, Yamamoto F, Yoshioka A. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995;68:236–240.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet 1999;353:227–231.
   PubMed Web of Science ®Google Scholar
• EPIC Study Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956–961.
   PubMedGoogle Scholar
• PURSUIT Trial Investigators. Inhibition of platelet glyco- protein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT final Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998; 339:436–443.
   Google Scholar
• IMPACT-II Study Investigators. Randomised placebo- controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997;349:1422–1428.
   Google Scholar
• PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488–1497.
   Google Scholar
• PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498–1505.
   Google Scholar
• EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein- IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87–92.
   Google Scholar
• CAPTURE Study Investigators. Randomised placebo- controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429–1435.
   PubMedGoogle Scholar
• RESTOR Investigators. Effects of platelet glycoprotein IIb/ IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997;96:1445–1453.
   Google Scholar
• Steinhubl SR. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study. J Thromb Thrombolysis 2000;9:199–205.
   PubMedGoogle Scholar
• Steinhubl SR, Talley JD, Braden GA, Tcheng JE, Casterella PJ, Moliterno DJ, Navetta FI, Berger PB, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001:103– 2572.
   Google Scholar
• Orstavik KH. Genetics of plasma concentration of von Willebrand factor. Folia Haematol Int Mag Klin Morphol Blutforsch 1990;117:527–531.
   PubMedGoogle Scholar
• Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985;37:89–101.
   Google Scholar
• Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69:1691–1695.
   PubMed Web of Science ®Google Scholar
• Kerr CB, Preston AE, Barr A, Biggs R. Inheritance of factor 8. Thromb Diath Haemorrh Suppl 1965;17:173–179.
   PubMedGoogle Scholar
• Kerr CB, Preston AE, Barr A, Biggs R. Further studies on the inheritance of factor 8. Br J Haematol 1966;12:212–233.
   PubMedGoogle Scholar
• Northfield TC. Factors predisposing to recurrent haemorrhage after acute gastrointestinal bleeding. Br Med J 1971;1:26–28.
   PubMed Web of Science ®Google Scholar
• Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 1994;88:601–607.
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PFA-100. Thromb Haemost 2001;85:369–370.
   PubMed Web of Science ®Google Scholar
• Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion 2001;41:56–60.
   PubMed Web of Science ®Google Scholar
• Hezard N, Metz D, Nazeyrollas P, Droulle C, Elaerts J, Potron G, Nguyen P. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb Haemost 2000;83:540–544.
   PubMed Web of Science ®Google Scholar